BOK cuts base rate by 0.25%p amid won's rally
The Bank of Korea cut the base rate by 0.25 percentage point, lowering it to 2.5 percent. With the decision, the gap between Korea's key rate and the US rate has widened from 1.75 percentage points to 2 percentage points.
The BOK implemented a rate cut, supported by recent strength in the Korean won against the greenback.
While a wider interest rate gap raises concerns over capital outflows and forex market volatility, the won's recent appreciation has mitigated these pressures.
With the rate cut, the central bank also slashed the projection for this year's gross domestic product growth from 1.5 percent to 0.8 percent.
The BOK's renewed projection is similar to estimates suggested by other institutions. The Korea Development Institute also halved its projection for this year from 1.6 percent to 0.8 percent.
The next rate-setting meeting is scheduled for July 10.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
![[Editorial] Focus on tariffs](/_next/image?url=https%3A%2F%2Fall-logos-bucket.s3.amazonaws.com%2Fkoreaherald.com.png&w=48&q=75){kind=small}
Korea Herald
an hour ago
- Korea Herald
[Editorial] Focus on tariffs
Unclear how negotiations are progressing; suitable special envoy must be sent to US President Lee Jae Myung presided over a general meeting of the National Security Council on July 10, three weeks before the US is scheduled to impose tariffs. People expected the meeting to deal mostly with the issue of negotiations with the US over its tariffs. But officials related to trade were absent from the meeting. During the meeting, Lee called for efforts to mend inter-Korean ties. He was also reportedly briefed by the Ministry of National Defense on security issues, including an early transition of wartime operational control. Reportedly, US tariffs, an issue at hand, were barely discussed. A Federation of Korean Industries survey released on July 11 found that 9 out of 10 Korean export companies said they could not cope with US tariffs if they go over 15 percent. The "reciprocal" tariff that US President Donald Trump vowed to levy on South Korea is 25 percent. The South Korean economy, buttressed by exports, could be in jeopardy if hit by high US tariffs. Companies and people feel uneasy, and yet it is unclear how tariff negotiations with the US are progressing. The South Korean trade minister met with the US Commerce Secretary twice in the US before returning home, but no agreement reportedly came out of the meetings. The national security adviser went to the US, too, arousing expectations for a package deal involving tariffs and security, but he came back without accomplishments to speak of. Meanwhile, an early transition of wartime operational control, not tariffs, attracted media attention at home. The government should focus on tariff negotiations at this time. Wartime operational control transition and inter-Korean ties seem out of step with the situation. Korea must consider its security reality: it lacks the ability to deter North Korea's nuclear attacks independently. An early takeover of wartime operational control from the US, if materialized, would have severe aftereffects as it is directly linked to US Forces Korea's readjustment and reduction. Seoul must not rush a decision on the issue but examine it prudently from various angles. It would be a foolish choice to first request that the US hand over wartime operational control. Korea's leading industries, including semiconductors, cars and steel, are sitting on the edge of a precipice due to the ticking US tariff bomb. The government in Seoul must concentrate on tariff negotiations to make a deal. Korea could consider increasing its defense budget and its share of USFK stationing costs as leverage in tariff negotiations. The trade minister fronts Korea's tariff negotiation team, but despite his title, he is only a vice-ministerial official under the Ministry of Trade, Industry and Energy. Tariffs that Trump vows to impose are an issue that could upset both Korea's economy and security. This is too grave a matter for a vice-ministerial official such as the trade minister to deal with. A summit is desirable to solve tariff issues, but no answer has come yet from the US. The national security adviser visited the US but there has been no talk of a summit. Less than three weeks remain until Aug. 1, when US tariffs will take effect. Yet signs of a forthcoming agreement are nowhere to be seen. To guard national interests in negotiations with the US, Korea must figure out Trump's intentions and let him know Seoul's positions properly. Sending a special envoy to the US could be one way of doing so. The envoy should not necessarily meet with the US president face-to-face. He or she should be able to contact a figure who understands Trump's mind and who can put Korea's demands across to him. As a special envoy, Korea needs an old hand at diplomacy toward the US who has a lot of personal connections and information. Some special envoy candidates reportedly under consideration seem to have no close ties with Trump and his surrounding people. Those who have remarked negatively about the US should be excluded. Lee must tap a wide pool of talent, including politicians, business people, former and current bureaucrats, overseas Koreans, scholars and so on.
Korea Herald
8 hours ago
- Korea Herald
Illimis Therapeutics Closes 58 billion KRW ($42 million) Series B Financing to accelerate CNS and Immune Disease Drug Development via GAIA Platform
SEOUL, South Korea, July 14, 2025 /PRNewswire/ -- The Series B round saw strong participation from both existing and new investors, demonstrating high industry confidence in Illimis Therapeutics' vision and technology. Eight existing investors, including DSC Investment, Woori Venture Partners, Korea Development Bank, Aju IB Investment, Quad Asset Management, Company K Partners, GS Ventures, and Dayli Partners, reaffirmed their commitment. They were joined by ten new investors: LB Investment, TS Investment, Shinhan Venture Investment, S&S Investment, Hana Ventures, Maple Investment Partners, A Ventures, IMM Investment, Schmidt, and Industrial Bank of Korea. The proceeds will be used to accelerate the development of GAIA-based Alzheimer's Disease therapeutics, expand its target indications to various immune disorders, and broaden its pipeline of potential blockbuster drug candidates. The company is actively pursuing early-stage collaborations with global pharmaceutical companies and research institutions to add value to internal programs. "In the evolving landscape of new drug development where the limitations of existing medications are continually being overcome, Illimis' differentiated platform technology is expected to emerge as a next-generation treatment option for neuro-immune diseases with high unmet medical needs," said Yohan Kim, Senior Managing Director at DSC Investment, who led this investment round and has also been appointed to the board of directors. Jiwoong Chun, Managing Director at Woori Venture Partners and an active board member and investor since the company's inception, added, "Illimis is a prime example of a smart Korean biotech unlocking global markets with proprietary innovation and capital efficiency." Illimis has recently been selected for the '2025 Global Joint Research to Defeat Dementia' led by the Ministry of Health and Welfare and the Korean Dementia Research Center, securing KRW 2.2 million ($1.6 million) in funding over three years, further validating its technological capabilities. This initiative aims to develop Alzheimer's therapeutics through global joint research leveraging the GAIA platform, positioning Illimis at the center of international collaboration. Furthermore, in October 2024, Illimis partnered with Eli Lilly and Company (Lilly)'s Catalyze360-ExploR&D, a core pillar of external innovation at Lilly dedicated to deploying world-leading research and development capabilities and scientific know-how to accelerate partner science. Under this research collaboration, Illimis and Lilly have been cooperating to advance the platform construct for applications in neurodegenerative diseases. Illimis has also strengthened its global pharma collaborations by winning the 2023 BMS Innovation Square Challenge and joining Johnson & Johnson's global incubator network as a member company of JLABS Singapore in 2024. To further enhance its drug development competitiveness, Illimis Therapeutics operates a Scientific Advisory Board (SAB). The SAB includes Dr. Greg Lemke, Emeritus Professor at the Salk Institute and a world-renowned expert in TAM Biology, and Dr. Morgan Sheng, a leading neuroscientist at the Broad Institute who previously served as Vice President of Neuroscience at Genentech. These experts provide strategic guidance across the entire R&D lifecycle, including pipeline development, candidate discovery, clinical trial design, etc., and play a pivotal role in strengthening Illimis Therapeutics' global partnerships. "This investment, government grants, and partnership with Lilly will enable us to accelerate our efforts to conquer diseases with high unmet clinical needs based on a comprehensive understanding of TAM biology and establish global leadership in TAM biology," said Sanghoon Park, CEO of Illimis Therapeutics. "We will continue to focus on innovative new drug development centered around the GAIA platform and provide tangible treatment options to patients worldwide through early R&D collaboration models." About Illimis Therapeutics Illimis Therapeutics is a pioneering biotechnology company at the forefront of developing innovative therapies for challenging central nervous system (CNS) and immune-related diseases. The company's core strength lies in its proprietary GAIA (Gas6-mediated Anti-Inflammatory Adaptor) platform. This cutting-edge platform is designed to harness the therapeutic potential of TAM (Tyro3, Axl, Mer) receptor biology, a critical pathway involved in regulating inflammation and immune responses. The company's lead pipeline, ILM01 for the treatment of Alzheimer's Disease, is entering into the preclinical stage in the second half of 2025 and expecting to submit an IND by the end of 2027. For more information, visit
Korea Herald
12 hours ago
- Korea Herald
‘Golden time to invest': Shinhan FDI unit targets global investors
From distressed assets to supply chain shifts, Korea gains appeal amid global uncertainty While South Korea faces headwinds from heightened uncertainty in the trade environment, Shinhan FDI partners, a specialized unit dedicated to providing support for foreign direct investment here, sees opportunities in challenges that lie ahead. 'Now is the golden time to invest in Korea,' said Jenny Hong, one member of the global investment support team of Shinhan FDI partners. Distinct from other forms of cross-border investment ― such as purchasing stocks and bonds ― foreign direct investment involves active asset management, including acquiring physical assets like factories or gaining management control of a company. 'The sluggish Korean economy is a favorable factor. With the local won weakening against the dollar, Korean assets are currently undervalued,' Hong explained. Foreign investors are also eyeing opportunities in distressed assets. For instance, overseas hedge funds are weighing to invest in the logistics sector through nonperforming loans, as the industry struggles with the fallout from collapsed project financing deals. Similar to its peers, Shinhan Bank plays a key role in facilitating inbound investment, as foreign investors have to report their investments to the Korea Trade-Investment Promotion Agency or foreign exchange banks under the Foreign Exchange Transactions Act. Previously, the specialized workforce supporting investments was scattered across various departments within the bank. The lender launched a centralized unit last month to streamline its services. 'With the rising complexity of deals, there was a clear need for a more coordinated approach. These days, we are seeing increasingly intricate stakeholder dynamics,' Hong said. 'Multiple parties are involved, ranging from private equity firms to joint ventures and other entities. Coordinating among all these stakeholders requires a more integrated approach." With the US, Japan and China being the three largest players in foreign direct investment for Korea, the team has regional experts dedicated to handling each market. Hong specializes in English-speaking firms, while Yang Zou and Ayako Yamoto focus on Chinese and Japanese firms, respectively. According to Yang, a growing number of Chinese companies are turning their attention to Korea as a potential detour around trade restrictions imposed by the US. 'With the Inflation Reduction Act of 2022 and the introduction of 'reciprocal' tariffs, Chinese investors are looking to mitigate risks by importing raw materials from China and manufacturing in Korea. This trend is driving increased investment in factory construction here,' Yang said. Yamoto has been working with an increasing number of consumer-oriented Japanese firms, as consumer preferences between Japan and Korea continue to align. 'While earlier investments primarily targeted business-to-business transactions, recent trends indicate a shift toward business-to-consumer models. An increasing number of consumer-oriented Japanese firms ― particularly those in the food and entertainment sectors ― are now eyeing the Korean market,' she said. The three "foreign corporate client relationship managers" highlighted that navigating offshore investors through the differing trade environment is the key mission for Shinhan FDI partners. 'There is a difference in investment practices across countries. For instance, some countries do not use seal imprints, whereas in Korea, corporate transactions require an official seal,' Hong said. Account opening procedures vary by country as well. 'When establishing a company in China, the process typically involves setting up the company first and then making the capital contribution afterward. In contrast, in Korea, the capital must be deposited first before the company is officially put on paper,' Yang said. 'From a Chinese investor's perspective, Korea's approach can be unsettling since the funds have to be secured before a company is established. It is my job to explain the process sufficiently.' While Korea has experienced a dip in the amount of pledged foreign direct investments this year, largely due to political uncertainty from the end of last year, the team projects the pace to pick up with increased clarity following the recent presidential election. In the first half of this year, foreign direct investment pledges to Korea totaled $13.1 billion, a decrease of 14.6 percent compared to the same period last year, according to the Trade Ministry. While actual FDI arrivals increased by 2.7 percent to $7.3 billion, the drop in pledged investments is still significant because it may signal reduced investor confidence and could impact future capital inflows. 'With the political uncertainty resolved, we anticipate increased interest from foreign investors. We are already receiving inquiries from potential investors,' Hong said. 'More foreign direct investment in Korea means more seed money for the country's economic growth. From a macroeconomic perspective, we find meaning in our work by financially supporting the nation's development. From another standpoint, we work to safeguard our clients by ensuring protection of their investments."
